在非恶性乳腺上皮细胞中,G蛋白亚型偏好决定了帕罗素增强的血清激素受体反应
Máté Lengyel1, Péter Árkosy2, Iván P Uray1
1Department of of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; The Molecular, Cell and Immune Biology Doctoral School, Faculty of Medicine, University of Debrecen, Debrecen, Hungary; Department Clinical Oncology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
选择性血清素再吸收抑制剂 (SSRI),如帕洛克,可以通过抑制非恶性乳腺细胞增殖来降低乳腺癌风险. 针对特定的血清素 (5-HT) 受体提供了一种新的方法来降低癌症风险.
科学领域:
- 细胞生物学 细胞生物学
- 药理学 药理学是指药理学的学科.
- 癌症研究 癌症研究
背景情况:
- 血清素 (5-HT) 影响乳腺组织形态,生长,哺乳和内发.
- 血清素再吸收抑制剂 (SSRI) 通过细胞增殖对乳腺癌风险的影响尚未完全理解.
研究的目的:
- 研究5-HT受体激活对非恶性乳腺细胞生长的影响.
- 评估SSRI和受体选择性剂在降低乳腺癌风险方面的潜力.
主要方法:
- 分析了转录和信号配置文件.
- 进行了对受体选择性连接体的系统选.
- 评估了帕洛克塞丁对不朽化初级乳腺上皮细胞 (HME-hTert) 的影响.
主要成果:
- 帕洛西丁降低了5-HT水平,自由氧基的形成,细胞迁移和增殖.
- 5-HT受体的激活,特别是5-HT7 (Gs-合),以及5-HT1D和5-HT2B (Gi / Gq-合) 受体的对抗性抑制了增殖.
- 帕洛西丁的增长抑制与Gs合的5-HT7受体活性有关.
结论:
- 在非恶性乳腺细胞中对5-HT的抗增殖反应与受体的G蛋白偏好相关.
- 重新定位SSRI并准特定的血清素受体,为减少乳腺癌风险提供了一个新的策略.
更多相关视频
12:21Thermostabilization, Expression, Purification, and Crystallization of the Human Serotonin Transporter Bound to S-citalopram
Published on: November 27, 2016
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
相关概念视频
G-protein Coupled Receptors
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Transducer Mechanism: G Protein–Coupled Receptors
GPCRs are also called heptahelical,...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCR Desensitization
